Background. Bladder cancer (BC) is one of the most serious genitourinary malignant diseases with a poor prognosis. Necroptosis is a regulated form of cell death, and targeting necroptosis is emerging as a potential tumor therapy strategy. Nevertheless, the roles of necroptosis-related long noncoding RNAs (nrlncRNAs) in BC remains to be illustrated. This work is aimed at studying the clinical implications of nrlncRNAs in BC. Methods. The RNA-seq data and corresponding clinical data, downloaded from The Cancer Genome Atlas (TCGA) database, were utilized to obtain prognostic nrlncRNAs and construct a prediction nomogram for BC. The comprehensive profiling of the functional pathways, immune status, mutational landscape, and drug sensitivity related to the necroptosis-related lncRNA signature (NerRLsig) was performed. Results. Herein, a signature consisting of 12 necroptosis-related lncRNAs (AC015802.4, AL391807.1, AL078644.1, AC023825.2, AL132655.2, AP003352.1, STAG3L5P-PVRIG2P-PILRB, AC024451.4, MAP3K14-AS1, AL731567.1, AC010542.5, and AC009299.2) was constructed. The established signature can independently predict the poor overall survival of BC patients. Additionally, the NerRLsig had higher diagnostic validity compared to other clinicopathological variables, with a greater area under the receptor operating characteristic and concordance index curves. Finally, we found the differences in the functional signaling pathway, immune status, mutational profile, and drug sensitivity between the two subgroups. Conclusion. This research revealed that the prognostic NerRLsig and nomogram could accurately predict the prognosis of BC.

Aims: Examine GTSE1 expression and function in renal clear cell carcinoma, as well as the nc-RNA that is upstream of GTSE1.Methods: The Cancer Genome Atlas (TCGA) provided clinical and RNA-seq data for ccRCC patients, and the expression of GTSE1, its connection with clinical data, prognosis and tumor immune infiltration, and prediction of upstream noncoding RNAs (nc-RNAs) of GESE1 were analyzed using R language and public tumor databases.Results: In ccRCC, GTSE1 is highly expressed and is linked to a high clinical stage and a poor prognosis. In ccRCC, the PVT1 / has-mir-23b-3p / GTSE1 axis has been identified as the most likely upstream ncRNA related route of GTSE1. Furthermore, GTSE1 expression was linked to tumor immune cell infiltration, immune cell biomarker expression, and immunological checkpoint expression.Conclusions: Upregulation of GTSE1 by ncRNA is linked to poor prognosis and ccRCC tumor immune infiltration. GTSE1 has the potential to be a useful predictive biomarker as well as a therapeutic target.